Eyevensys appoints new CEO
This article was originally published in Scrip
Dr Cohen-Tanugi
Eyevensys, a company developing a non-viral gene therapy process for ocular illnesses, has named Dr Ivan Cohen-Tanugi chief executive officer. Prior to joining the company – which targets two main indications of uveitis and age-related macular degeneration disease – Dr Cohen-Tanugi served as vice-president and general manager, biologics and specialty unit, at Teva Pharmaceuticals.